Annual report pursuant to Section 13 and 15(d)

Quarterly Data (Unaudited) (Details)

v3.6.0.2
Quarterly Data (Unaudited) (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 11 Months Ended 12 Months Ended
Dec. 31, 2016
Sep. 30, 2016
Jun. 30, 2016
Mar. 31, 2016
Dec. 31, 2015
Sep. 30, 2015
Jun. 30, 2015
Mar. 31, 2015
Dec. 31, 2014
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Revenue $ 2,587 $ 1,596 $ 1,552 $ 8,486 $ 1,943 $ 2,915 $ 2,114 $ 1,689   $ 14,221 $ 8,661 $ 5,327
Gross profit 843 403 203 1,498 (194) 468 502 403   2,947 1,179 1,559
Net income (loss) (5,576) (8,478) (5,765) (3,651) (4,645) (5,185) (5,645) (4,115) $ (33,769) (23,470) (19,590) (33,769)
Net loss attributable to common shareholders $ (5,576) $ (11,494) $ (9,970) $ (6,775) $ (9,300) $ (5,185) $ (5,645) $ (4,115)   $ (33,815) [1] $ (24,245) $ (33,769)
Basic net loss per share (In dollars per share) $ (0.29) [2] $ (0.60) [2] $ (0.61) [2] $ (0.44) [2]           $ (1.87) [1] $ (1.66) $ (3.02)
Diluted net loss per share (In dollars per share) $ (0.35) [2] $ (0.60) [2] $ (0.61) [2] $ (0.44) [2]           $ (2.05) [1] $ (1.83) $ (3.02)
Basic and diluted net loss per share (In dollars per share) [2]         $ (0.63) $ (0.35) $ (0.39) $ (0.28)        
[1] Recognition of previously deferred revenue and cost of goods in the year ended December 31, 2016 reduced net loss applicable to common stockholders by $2,358, or $0.13 per share (see Note 2. Basis of Presentation and Summary of Significant Accounting Policies and Estimates – Medical Device Revenue and Cost of Revenue Recognition).
[2] Quarterly net loss per common share amounts may not total to the annual amounts due to rounding and the changes in the number of weighted common shares outstanding and included in the calculation of basic and diluted common shares.